Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, AXS-12, AXS-14 and AXS-17. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Company Information
About this company
Key people
Herriot Tabuteau
Chairman of the Board, President, Chief Executive Officer, Founder
Nick Pizzie
Chief Financial Officer
Mark L. Jacobson
Chief Operating Officer
Hunter Murdock
General Counsel
Ari Maizel
Chief Commercial Officer
Mark Coleman
Lead Independent Director
Roger A. Jeffs
Independent Director
Susan M. Mahony
Independent Director
Mark E. Saad
Independent Director
Click to see more
Key facts
- Shares in issue50.41m
- EPICAXSM
- ISINUS05464T1043
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$8.66bn
- Employees683
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.